Dimension Therapeutics (NASDAQ:DMTX)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research note issued on Friday.
The analysts wrote, “We believe 2017 has been an even better year fundamentally, on the expansion of breakthrough results, the first 3 GT approvals in the US, sector late-stage momentum, sound safety, and other considerations below. We now make uniQure (Buy) a Chardan Top Pick for 2018 and a Chardan Top Pick in Gene Therapy for 2018.””
Other research analysts have also issued reports about the company. Citigroup raised Dimension Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $5.50 to $6.00 in a research report on Tuesday, October 3rd. Canaccord Genuity lowered Dimension Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $12.00 to $3.41 in a research report on Wednesday, August 30th. Wells Fargo & Company lowered Dimension Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $9.00 to $6.00 in a research report on Tuesday, October 3rd. Finally, ValuEngine raised Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $5.08.
Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.20). The company had revenue of $4.48 million during the quarter. Dimension Therapeutics had a negative return on equity of 240.95% and a negative net margin of 378.28%. research analysts anticipate that Dimension Therapeutics will post -1.99 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. K2 Principal Fund L.P. purchased a new position in Dimension Therapeutics during the 3rd quarter worth $960,000. Kassirer Asset Management Corp purchased a new position in Dimension Therapeutics during the 3rd quarter worth $952,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Dimension Therapeutics during the 3rd quarter worth $600,000. Finally, Goldman Sachs Group Inc. grew its stake in Dimension Therapeutics by 206.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after buying an additional 54,231 shares during the last quarter. 70.33% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/22/dimension-therapeutics-dmtx-buy-rating-reaffirmed-at-chardan-capital.html.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.